This month's issue features 12 reports of current research on major depression and bipolar disorder. Seven examine use of medications. Alisa B. Busch, M.D., M.S., and colleagues, who looked at a national data set, found that during the 1990s, patients with bipolar disorder were increasingly likely to receive guideline-concordant pharmacotherapy but less likely to receive psychotherapy (page 27). David M. Gardner, Pharm.D., M.Sc., and coauthors asked 127 patients and 110 physicians to rank 12 factors relevant to selecting an antidepressant and found moderate disagreement about their importance, which may have implications for treatment adherence (page 34). An analysis of data from 665 addiction treatment programs led Hannah K. Knudsen, Ph.D., and colleagues to conclude that African-American and Hispanic clients had less access to selective serotonin reuptake inhibitors (page 55). Colette B. Raymond, Pharm.D., and coauthors report that although the prevalence of antidepressant use in British Columbia doubled between 1996 and 2004, the incidence of use (initiation of an antidepressant) decreased after 1999 (page 79). Ross J. Baldessarini, M.D., and colleagues found that the initially prescribed monotherapy for 7,760 patients with bipolar disorder was an antidepressant—prescribed for 50%—followed by mood stabilizers (including lithium) for 25%, and sedatives for 15% (page 85). A Veterans Affairs study by Michael J. Sernyak, M.D., and Robert A. Rosenheck, M.D., revealed that generic fluoxetine was prescribed for relatively few depressed patients in the year after it became available, even though its use would have decreased annual medication costs from $3.2 million to $311,000 (page 128). Michael A. Fischer, M.D., M.S., and colleagues report that of the 30 state Medicaid programs that required prior authorization for antidepressant prescriptions in 2005, eight had specific provisions for children (page 135).